Compare IPCA Labs with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs WOCKHARDT - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS WOCKHARDT IPCA LABS/
WOCKHARDT
 
P/E (TTM) x 21.8 -86.9 - View Chart
P/BV x 7.8 1.9 405.2% View Chart
Dividend Yield % 0.2 0.0 7,756.5%  

Financials

 IPCA LABS   WOCKHARDT
EQUITY SHARE DATA
    IPCA LABS
Mar-19
WOCKHARDT
Mar-18
IPCA LABS/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1,0421,012 103.0%   
Low Rs590532 111.0%   
Sales per share (Unadj.) Rs298.6355.9 83.9%  
Earnings per share (Unadj.) Rs35.0-60.3 -58.1%  
Cash flow per share (Unadj.) Rs49.4-46.8 -105.7%  
Dividends per share (Unadj.) Rs3.000.01 30,000.0%  
Dividend yield (eoy) %0.40 28,371.4%  
Book value per share (Unadj.) Rs247.1257.8 95.9%  
Shares outstanding (eoy) m126.35110.63 114.2%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.72.2 126.0%   
Avg P/E ratio x23.3-12.8 -182.1%  
P/CF ratio (eoy) x16.5-16.5 -100.0%  
Price / Book Value ratio x3.33.0 110.3%  
Dividend payout %8.60 -51,667.0%   
Avg Mkt Cap Rs m103,10885,379 120.8%   
No. of employees `00013.46.3 214.9%   
Total wages/salary Rs m7,8749,371 84.0%   
Avg. sales/employee Rs Th2,807.06,295.0 44.6%   
Avg. wages/employee Rs Th585.81,498.3 39.1%   
Avg. net profit/employee Rs Th329.0-1,066.3 -30.9%   
INCOME DATA
Net Sales Rs m37,73239,369 95.8%  
Other income Rs m5771,202 48.0%   
Total revenues Rs m38,30940,571 94.4%   
Gross profit Rs m6,90118 37,708.7%  
Depreciation Rs m1,8241,495 122.0%   
Interest Rs m1892,555 7.4%   
Profit before tax Rs m5,465-2,830 -193.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,042257 405.6%   
Profit after tax Rs m4,422-6,669 -66.3%  
Gross profit margin %18.30 39,344.9%  
Effective tax rate %19.1-9.1 -210.0%   
Net profit margin %11.7-16.9 -69.2%  
BALANCE SHEET DATA
Current assets Rs m23,77833,796 70.4%   
Current liabilities Rs m10,97526,917 40.8%   
Net working cap to sales %33.917.5 194.2%  
Current ratio x2.21.3 172.6%  
Inventory Days Days10479 130.8%  
Debtors Days Days6689 73.9%  
Net fixed assets Rs m20,36839,664 51.4%   
Share capital Rs m253553 45.7%   
"Free" reserves Rs m30,97127,968 110.7%   
Net worth Rs m31,22428,522 109.5%   
Long term debt Rs m1,40921,731 6.5%   
Total assets Rs m45,50781,620 55.8%  
Interest coverage x30.0-0.1 -27,864.1%   
Debt to equity ratio x00.8 5.9%  
Sales to assets ratio x0.80.5 171.9%   
Return on assets %10.1-5.0 -201.0%  
Return on equity %14.2-23.4 -60.6%  
Return on capital %17.3-7.7 -225.7%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,3089,807 176.5%   
Fx outflow Rs m6,2661,789 350.4%   
Net fx Rs m11,0428,019 137.7%   
CASH FLOW
From Operations Rs m4,923684 719.3%  
From Investments Rs m-1,5636,302 -24.8%  
From Financial Activity Rs m-1,832-7,695 23.8%  
Net Cashflow Rs m1,528-664 -230.1%  

Share Holding

Indian Promoters % 45.9 74.5 61.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 2.3 495.7%  
FIIs % 25.3 7.7 328.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.4 15.4 113.0%  
Shareholders   36,892 67,757 54.4%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Plunges 158 Points; Indicates Gap-Down Opening for Indian Stock Markets(SGX Nifty)

The SGX Nifty opened on a negative note today. At 8:10 am, it was trading down by 158 points, or 1.1% lower at 14,912 levels.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Mar 5, 2021 09:12 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS